Key result
Linagliptin treatment reduced albuminuria and attenuated kidney injury in a mouse model of type 2 diabetic nephropathy, independent of glucose and blood pressure.
Why the study?
Does linagliptin reduce albuminuria and kidney injury in a mouse model of type 2 diabetic nephropathy?
Does linagliptin reduce albuminuria and kidney injury in a mouse model of type 2 diabetic nephropathy?
Linagliptin demonstrates renoprotective effects in a mouse model of type 2 diabetic nephropathy independent of its glucose-lowering effects.
Answers are grounded in this paper and cite their sources.
Linagliptin attenuates diabetic kidney injury in mice beyond glycemic effects; leaves open translation to human nephropathy.
BACKGROUND: Despite the beneficial effects of type 4 dipeptidyl peptidase (DPP-4) inhibitors on glucose levels, its effects on diabetic nephropathy remain unclear. METHOD: This study examined the long-term renoprotective effects of DPP-4 inhibitor linagliptin in db/db mice, a model of type 2 diabetes. Results were compared with the known beneficial effects of renin-angiotensin system blockade by enalapril. Ten-week-old male diabetic db/db mice were treated for 3 months with either vehicle (n = 10), 3 mg linagliptin/kg per day (n = 8), or 20 mg enalapril/kg per day (n = 10). Heterozygous db/m mice treated with vehicle served as healthy controls (n = 8). RESULTS: Neither linagliptin nor enalapril had significant effects on the parameters of glucose metabolism or blood pressure in diabetic db/db mice. However, linagliptin treatment reduced albuminuria and attenuated kidney injury. In addition, expression of podocyte marker podocalyxin was normalized. We also analysed DPP-4 expression by immunofluorescence in human kidney biopsies and detected upregulation of DPP-4 in the glomeruli of patients with diabetic nephropathy, suggesting that our findings might be of relevance for human kidney disease as well. CONCLUSION: Treatment with DPP-4 inhibitor linagliptin delays the progression of diabetic nephropathy damage in a glucose-independent and blood-pressure-independent manner. The observed effects may be because of the attenuation of podocyte injury and inhibition of myofibroblast transformation.
No takes yet. Share an insight, caveat, or question.
Sharkovska et al. (2014) studied Type 2 diabetic nephropathy (n=36). Linagliptin vs. Vehicle and enalapril was evaluated on Albuminuria and kidney injury. Linagliptin treatment reduced albuminuria and attenuated kidney injury in a mouse model of type 2 diabetic nephropathy, independent of glucose and blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: